<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305314</url>
  </required_header>
  <id_info>
    <org_study_id>GERMFIS2020</org_study_id>
    <nct_id>NCT04305314</nct_id>
  </id_info>
  <brief_title>Long-term Enlarged Survival After an Enhanced Recovery Protocol (LESAS).</brief_title>
  <acronym>LESAS</acronym>
  <official_title>Surgical Treatment of Colorectal Cancer: Analysis of the Influence of an Enhanced Recovery Protocol on Long-term Oncological Outcomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Rehabilitación Multimodal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigación Sanitaria Aragón</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Rehabilitación Multimodal</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to analyze the impact on three years survival of an
      enhanced recovery program (PRI) after radical surgery for colorectal cancer. As secondary
      objectives, we propose to analyze the weight of each of the predefined items in the
      oncological results as well as the quality of life.

      We design a multicentric prospective cohort study in people older than 18 years who are going
      to be operated on for colorectal cancer. 12 hospitals are being selected due to have a PRI
      implanted according to the RICA pathway published by the Spanish National Health Service. As
      stated by the literature, the intervention group will be formed for those hospitals with a
      minimum implementation level of 70% of the PRI and the control group will be the centers that
      do not reach this level of implementation. Compliance will be studied with 21 key performance
      indicators and results are analyzed with cancer survival indicators: Overall survival,
      cancer-specific survival and relapse-free survival). We will also study the time to
      recurrence, perioperative morbi-mortality, hospital stay and quality of life with the EQ-5D
      validated questionary.

      To create comparable treatment and control groups, the Propensity Index method will be used.
      To study each variable, multivariate regression will be used. Kaplan-Meier will be used for
      survival and the log-rank test for comparisons. Significance will be considered if p &lt;0.05
      (two tails).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects of study (inclusion criteria): All patients over 18 years of age who will be
      operated on a scheduled basis for colorectal cancer within an intensified recovery program
      (PRI) and who do not present any exclusion criteria.

      Exclusion Criteria: - Urgent surgery; -Existence of other concomitant surgical processes;
      -Patients diagnosed in stage IV cancer; -Patients who refuse to participate.

      Participating hospitals: Selected for their interest in intensified recovery and for having
      established a multidisciplinary team with the program (PRI) for colorectal surgery
      recommended by the Spanish Ministry of Health. Each center will select from the
      multidisciplinary team the researchers who will be part of this project as collaborators,
      ideally the facilitators of the PRI program in that center.

      Variables: Patients will be recruited by local researchers from the Anesthesiology and
      Resuscitation and/or General Surgery services of each participating center before performing
      the surgical intervention. Informed consent will be requested from all subjects who
      voluntarily participate in the study.

        1. Compliance: As we have commented before and according to the literature, we will define
           a hospital with an intensified recovery program (PRI) that has a consensus protocol,
           based on evidence, multidisciplinary, with the support of the center (management) and
           that has fulfilled more than 70% of the protocol (annex 1) according to the process
           indicators. The rest of the hospitals will be considered a non-PRI hospital.

        2. Demography: Age, sex, BMI, smoking and fitness level of the American Society of
           Anesthesiologists (ASA). BMI in the surgical indication. Blood transfusion.

        3. Comorbidities: Presence of hypertension, diabetes mellitus, coronary artery disease,
           heart failure, cirrhosis, stroke or transient ischemic attack, COPD / Asthma, atrial
           fibrillation, heart failure, OSAS. Anemia

        4. Related to Surgery and Treatment: Date IQ. Surgical procedure, approach, duration of
           surgery, estimated bleeding. Curative surgery (R0) or non-R0 (R1-R2). Adjuvant
           chemotherapy Adjuvant radiotherapy Perioperative transfusion.

        5. Variables related to staging: Tumor typology. Growth pattern. Degree of differentiation.
           Presence of Vascular / lymphatic / perineural invasion / Satellites. Margin affectation.
           Seal ring cells. K-ras. T tumor piece. No tumor piece. Tumor m. Tumor stage according to
           AJCC classification.

        6. Related to the follow-up:

      In-hospital complications at 30 days of follow-up that will be recorded are: surgical
      complications, infectious complications, cardiovascular complications and other types of
      complications. Each complication will be classified as mild, moderate or severe.
      Perioperative mortality: The number and percentage of deaths within 30 days of surgery.
      Hospital Stay: hospital stay is defined as the duration in days from the date of admission to
      hospital discharge. Quality of life according to the EuroQol Five questionnaire. (EQ-5D).

      Overall mortality: The number and percentage of deaths occurred since the intervention until
      the end of the follow-up period. Overall survival: patients alive from surgery to the last
      control. Disease-free survival: number of patients alive and without cancer recurrence from
      the intervention period until the end of follow-up.

      Disease recurrence: detected by CT or FCC, from the day of the intervention until the end of
      the follow-up.

      Patient Follow-up Plan: 5 years after surgery. Data collection: The data will be collected in
      individual hospitals on a paper CRD for each patient recruited. This will include patient
      identification data in order to allow monitoring of clinical results. The data will be
      encoded by generating a unique numerical code and transcribed by local researchers in a
      database using an electronic CRD (eCRD). The data collection platform used will be Castor EDC
      https://www.castoredc.com/. Castor EDC complies with all applicable laws and regulations:
      good clinical practice (GCP), 21 CFR Part 11, EU Annex 11 and the European Data Protection
      Directive. Each patient will only be identified in the electronic CRD by their numerical
      code. In each center a list of patients will be used to match the identification codes of the
      individual patients' database in order to record the clinical results and provide any of the
      missing data. All identifiable data collected, processed and stored for the purposes of the
      project will be kept confidential at all times and will comply with the guidelines of Good
      Clinical Practice for Research (GCP) and the General Data Protection Regulation (GDPR)
      (Regulation (EU) ) 2016/679).

      Data analysis: Sample size: understanding, according to the literature, that only 60% of the
      centers with a PRI achieve more than 70% of compliance, we consider the scenario of 6 PRI and
      4 non-PRI centers adequate among the 10 who collaborate in this research project. Estimating
      a difference in overall survival between centers around 10% (65% vs. 75%), with a power of
      80%, a 95% confidence and 5% of possible losses, a minimum sample size of 366 is estimated
      patients in each group (732 patients in total). For the study of survival, only patients with
      a minimum follow-up of two years (first 12 months of the study) will be considered. However,
      they will continue to be recruited until the end of the three years for the study of
      secondary objectives.

      Understanding that the main objective, study of survival, may be subject to inherent aspects
      of each center, independent of the intervention, it is necessary to create comparable
      treatment and control groups for which the Propensity Score (Propensity Score Matching)
      method will be used. A descriptive analysis of the data will be carried out: Qualitative
      variables will be presented by frequency distribution of the percentages of each category.
      The quantitative variables studied will be explored with the Kolmogorov - Smirnov conformity
      test. Bivariate Analysis Comparison between variables (factors): The association between the
      factors will be investigated by hypothesis contrast tests, with comparison of proportions
      when both variables are qualitative (chi square, Fisher's exact test), mean comparisons when
      one of them is quantitative (Student's t, ANOVA, and if they do not follow the normal
      distribution, the Mann-Whitney U test or the Kruskall-Wallis test) and bivariate correlations
      (Coef. Pearson Correlation) when both are quantitative or, if the conditions are not met of
      application, the Spearman correlation. For comparisons in related samples when one of them is
      quantitative, Student's t-test and/or ANOVA will be used for repeated measurements and
      Wilcoxon or Friedman's test when do not follow normal distribution). Multivariate analysis:
      To study the relationship of each variable controlling the possible effect caused by third
      variables. The analysis will be completed using multivariate regression models. Survival
      analyzes will be performed using the Kaplan-Meier method for survival comparisons the
      log-rank test will be used. The effects will be considered significant if p &lt;0.05.

      Monitoring and audit: The data collection documents will be audited to ensure that study
      activities are carried out in accordance with the protocol, good clinical practice and
      applicable regulatory requirements. In the participating hospitals, local study documents can
      be selected for local auditing. The quality of the data will be audited.

      Limitations of the study: Those of a prospective non-randomized study. Difficulty in
      recruiting patients for potential structural or multidisciplinary team problems.
      Inappropriate number of patients in any of the arms due to a very high or very low level of
      compliance.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>patients alive from surgery to the last control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specific cancer survival.</measure>
    <time_frame>5 years</time_frame>
    <description>number of patients alive and without cancer recurrence from the intervention period until the end of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance and survival</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the relationship between adherence to the protocol and 5-year survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Item value</measure>
    <time_frame>5 years</time_frame>
    <description>To analyze the importance of each of the predefined items in 5-year survival</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Major Surgery</condition>
  <arm_group>
    <arm_group_label>Group 1: PRI &gt; 70%</arm_group_label>
    <description>Compliance with the Enhanced Revovery protocol higher than 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: PRI &lt; 70%</arm_group_label>
    <description>Compliance with the Enhanced Revovery protocol lower than 70%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRI (Enhanced Recovery after surgery protocol)</intervention_name>
    <description>Standard use of Spanish perioperative guidelines (PRI)</description>
    <arm_group_label>Group 1: PRI &gt; 70%</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Multicenter prospective observational cohort study in patients who meet inclusion criteria
        (18 years of age who will be operated on a scheduled basis for colorectal cancer ) in
        participating hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients over 18 years of age who will be operated on a scheduled basis for
             colorectal cancer

        Exclusion Criteria:

          -  - Urgent surgery; -Existence of other concomitant surgical processes; -Patients
             diagnosed in stage IV cancer; -Patients who refuse to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Luis Muñoz Rodés, PhD</last_name>
      <email>jlmunyoz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eva Miranda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Sanchez Guillen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Arroyo Sebastian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Antonio Garcia Erce, Phd</last_name>
      <email>jagarciaerce@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José Antonio García Erce, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Salvador Bravo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta P Martín Vizcaíno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Javier Yoldi Murillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuela Rubial Álvarez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susana Hernández García</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabiola Oteiza Martínez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Balén Ribera</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Estrella Petrina Jauregui</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Zugasti Murillo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Ribera</name>
      <address>
        <city>Alzira</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Blanco</last_name>
      <email>franciscojavierblancosurg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Alvarez Martinez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Estibaliz Echazarreta Gallego</last_name>
      <email>esti.egallego@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristina Latre Saso</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ramón Rodríguez Fraile</last_name>
      <email>jrrodriguezf@sescam.jccm.es</email>
    </contact>
    <investigator>
      <last_name>Mercedes Caballeros Olivares</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alba Manuel Vazquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Emilio Del Valle Hernández, Prof</last_name>
      <email>emilio.valle@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>José Pérez Peña, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Miguel Jimenez Jimenez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Jimenz diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Leon Arellano</last_name>
      <email>miguel.leon.arellano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Damian Garcia Olmo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hector Guadalajara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfredo Abad Gurumeta, MD</last_name>
      <phone>649337762</phone>
      <email>alfredoabadgurumeta@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ane Abad Motos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Ripollés Melchor, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Sáez Ruiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rut Salvachua, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norma Aracil Escoda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatriz Nozal Mateo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Palencia</name>
      <address>
        <city>Palencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Eugenia Centeno Robles</last_name>
      <email>meugeniacenteno@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Redondo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carolina Matinez Perez</last_name>
      <email>carolinamartinezperez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Biosca Perez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Manuel Ramírez Rodriguez, Prof</last_name>
      <email>jramirez@unizar.es</email>
    </contact>
    <investigator>
      <last_name>Manuela Elia Guedea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Córdoba Díaz de Laspra</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomás Ruiz Garcés</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Longás Valien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Ocon Breton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Martínez Ubieto</last_name>
      <email>jmtezubieto@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Pascual Bellosta</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Ortega Lucea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

